Nucleus Basalis Cholinergic In Alzheimer Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
| Property | Value |
|---|---|
| Category | Cholinergic System |
| Location | Nucleus basalis of Meynert, basal forebrain |
| Cell Type | Cholinergic projection neurons (CHAT+) |
| Projection | Cortex, hippocampus, amygdala |
| Neurotransmitter | Acetylcholine (ACh) |
The basal forebrain cholinergic system comprises several interconnected nuclei:
NBM neurons project widely to:
Medial septum cholinergic neurons project to:
Muscarinic receptors (GPCR):
Nicotinic receptors (ligand-gated):
The cholinergic anti-inflammatory pathway modulates neuroinflammation:
This pathway is relevant to AD where neuroinflammation contributes to pathology.
| Marker | Change in AD | Clinical Impact |
|---|---|---|
| ChAT activity | -40 to -70% | Reduced ACh synthesis |
| VAChT | -50% | Impaired vesicular filling |
| Muscarinic M1 | -30% | Signal transduction deficits |
| Nicotinic α4β2 | -40% | Receptor loss |
| Acetylcholine | -25 to -50% | Synaptic transmission failure |
First-line symptomatic treatments:
The study of Nucleus Basalis Cholinergic In Alzheimer Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res. 2011;221(2):555-563. DOI:10.1016/j.bbr.2010.11.058
Hampel H, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain. 2019;142(7):1913-1927. DOI:10.1093/brain/awz071
Ballinger EC, et al. Basal forebrain cholinergic circuitry and cognition: Insights from selective lesions and optogenetic stimulation. Brain Res. 2019;1707:16-28. DOI:10.1016/j.brainres.2018.10.044
Mufson EJ, et al. cholinergic system during the progression of Alzheimer's disease: Therapeutic implications. J Neural Transm (Vienna). 2022;129(5-6):667-697. DOI:10.1007/s00702-022-02492-5
Haam J, Yakel JL. Cholinergic modulation of hippocampal network function. Front Synaptic Neurosci. 2021;13:682001. DOI:10.3389/fnsyn.2021.682001
Liu AKL, et al. Review: Bringing back the cholinergic neurons in Alzheimer's disease. J Alzheimers Dis. 2023;94(s1):S1-S16. DOI:10.3233/JAD-220732
Catala I, et al. Nucleus basalis of Meynert: A key structure in brain aging and Alzheimer's disease. Ageing Res Rev. 2023;84:101834. DOI:10.1016/j.arr.2023.101834
Bohnen NI, et al. Cholinergic neuron loss in prodromal Alzheimer disease: Implications for early detection and treatment. Ann Neurol. 2022;92(3):415-427. DOI:10.1002/ana.26434